ArticleEuropean journal of clinical pharmacology2005
Statin-macrolide interaction risk: a population-based study throughout a general practice database.
Article in European journal of clinical pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of statin-drug interactions in older people: a systematic review.European journal of clinical pharmacology · 2016Pooled it
- Evaluation of dental practitioners' knowledge and attitudes regarding drug interactions: a cross-sectional survey.BMC oral health · 2026Article
- Improving lipid-lowering treatment and cardiovascular risk management in primary care: findings from an audit and feedback project.Frontiers in pharmacology · 2026Article
- Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Lycopene andPharmaceuticals (Basel, Switzerland) · 2024Article
- Effects of a Dietary Supplement Composed of Baicalin, Bromelain and Escin for Venous Chronic Insufficiency Treatment: Insights from a Retrospective Observational Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study.BMC pharmacology & toxicology · 2019Observational
- Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study.Frontiers in pharmacology · 2018Article
- Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017Article
- The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy.Clinical drug investigation · 2016Article
- Prevalence of Potential and Clinically Relevant Statin-Drug Interactions in Frail and Robust Older Inpatients.Drugs & aging · 2015Article
- Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011.British journal of clinical pharmacology · 2015Article
- Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study.PloS one · 2015Observational
- Chronic kidney disease requiring healthcare services: a new approach to evaluate epidemiology of renal disease.BioMed research international · 2014Article
- Article
- Article
- Don't blame the bones!European journal of nuclear medicine and molecular imaging · 2011Article
- Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07.British journal of clinical pharmacology · 2010Article
- Evidence-Based Knowledge Management: an approach to effectively promote good health-care decision-making in the Information Era.Internal and emergency medicine · 2009Article
- Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision.European journal of clinical pharmacology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe myopathy risk associated with statin use increases in case of concomitant prescription of certain drugs, such as cytochrome P(450) (CYP) system inhibitors (i.e., macrolides). The aim of this study was to assess whether concurrent statin/macrolide prescriptions at high interaction risk are commonly written in a general practice setting.
methodsFor this study, 156 general practitioners (GPs) with a patient population of almost 200,000 individuals, and participating in the Arianna database set up by "Caserta-1" Local health-Service Agency (ASL), were recruited. Within such a study sample, subjects receiving at least one statin/macrolide concomitant prescription during the year 2003 were identified. Sensitivity analysis was performed to assess the time distribution of high-risk macrolide prescriptions written within +/-10 days from the statin prescription date.
resultsAmong 190,124 patients included in the study, 7,176 (3.8%) received at least one statin prescription during the observation period. Of these, 228 (3.2%) were occasionally co-prescribed with any macrolide on the same date, in 153 cases (2.1% of statin users) the macrolide being of high interaction risk. In particular, 2.1% (55) of simvastatin users and 2.2% (64) of patients on atorvastatin were prescribed with high-risk macrolide on the same date versus 0.6% and 1.8% of patients prescribed with fluvastatin and pravastatin, respectively. Concerning GPs, 99 (63.5%) co-administered statin and macrolide at high interaction risk at least once.
conclusionsMost GPs occasionally prescribed statin/macrolide at high interaction risk on the same date, despite the availability of therapeutic alternatives. Prevention strategies targeted to increase awareness of health professionals about the interaction risks of widely prescribed drugs are needed.
Indexed as
Identifiers
16044339What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.